Legend Biotech Corp Comprehensive Income Attributable To Owners Of Parent
Legend Biotech Corp (LEGN) reported Comprehensive Income Attributable To Owners Of Parent of -$40.19 million for the 3-month period ending 2025-03-31, per its 6-K filed 2025-05-13.
Financial Statements › Income Statement › Unrealized Gains
ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent · last filed 2025-05-13
- Legend Biotech Corp comprehensive income attributable to owners of parent for the quarter ending 2025-03-31 was -$40.19M.
- Legend Biotech Corp comprehensive income attributable to owners of parent for the quarter ending 2024-12-31 was -$89.55M.
- Legend Biotech Corp comprehensive income attributable to owners of parent for the quarter ending 2024-09-30 was -$63.42M.
- Legend Biotech Corp comprehensive income attributable to owners of parent for the quarter ending 2024-06-30 was -$28.73M.
| Period end | Comprehensive Income Attributable To Owners Of Parent 3 month | Comprehensive Income Attributable To Owners Of Parent 6 month | Comprehensive Income Attributable To Owners Of Parent 9 month | Comprehensive Income Attributable To Owners Of Parent 12 month | Comprehensive Income Attributable To Owners Of Parent 12 month as first filed |
|---|---|---|---|---|---|
| 2025-03-31 | -$40.19M 6-K · filed 2025-05-13 | -$129.74M derived: sum of 2 quarters · filed 2025-05-13 | -$193.16M derived: sum of 3 quarters · filed 2025-05-13 | -$221.89M derived: sum of 4 quarters · filed 2025-05-13 | |
| 2024-12-31 | -$89.55M derived: 20-F 12 month − 6-K 9 month · filed 2025-03-11 | -$152.97M derived: sum of 2 quarters · filed 2025-03-11 | -$181.70M derived: sum of 3 quarters · filed 2025-03-11 | -$289.49M 20-F · filed 2025-03-11 | |
| 2024-09-30 | -$63.42M derived: 6-K 9 month − 6-K 6 month · filed 2024-11-12 | -$92.15M derived: sum of 2 quarters · filed 2024-11-12 | -$199.94M 6-K · filed 2024-11-12 | -$301.42M derived: sum of 4 quarters · filed 2025-05-13 | |
| 2024-06-30 | -$28.73M derived: 6-K 6 month − 6-K 3 month · filed 2024-08-09 | -$136.52M 6-K · filed 2024-08-09 | -$238.00M derived: sum of 3 quarters · filed 2025-05-13 | -$320.45M derived: sum of 4 quarters · filed 2025-05-13 | |
| 2024-03-31 | -$107.79M 6-K · filed 2025-05-13 | -$209.27M derived: sum of 2 quarters · filed 2025-05-13 | -$291.71M derived: sum of 3 quarters · filed 2025-05-13 | -$497.81M derived: sum of 4 quarters · filed 2025-05-13 | |
| 2023-12-31 | -$101.48M derived: 20-F 12 month − 6-K 9 month · filed 2025-03-11 | -$183.93M derived: sum of 2 quarters · filed 2025-03-11 | -$390.03M derived: sum of 3 quarters · filed 2025-03-11 | -$488.62M 20-F · filed 2025-03-11 | |
| 2023-09-30 | -$82.45M derived: 6-K 9 month − 6-K 6 month · filed 2024-11-12 | -$288.55M derived: sum of 2 quarters · filed 2024-11-12 | -$387.14M 6-K · filed 2024-11-12 | -$514.35M derived: sum of 4 quarters · filed 2025-03-11 | |
| 2023-06-30 | -$206.10M derived: 6-K 6 month − 6-K 3 month · filed 2024-08-09 | -$304.69M 6-K · filed 2024-08-09 | -$431.90M derived: sum of 3 quarters · filed 2025-03-11 | -$521.05M derived: sum of 4 quarters · filed 2025-03-11 | |
| 2023-03-31 | -$98.59M 6-K · filed 2024-05-13 | -$225.81M derived: sum of 2 quarters · filed 2025-03-11 | -$314.95M derived: sum of 3 quarters · filed 2025-03-11 | ||
| 2022-12-31 | -$127.21M derived: 20-F 12 month − 6-K 9 month · filed 2025-03-11 | -$216.35M derived: sum of 2 quarters · filed 2025-03-11 | -$436.54M 20-F · filed 2025-03-11 | ||
| 2022-09-30 | -$89.14M derived: 6-K 9 month − 6-K 6 month · filed 2023-11-20 | -$309.33M 6-K · filed 2023-11-20 | |||
| 2022-06-30 | -$220.19M 6-K · filed 2023-08-15 | ||||
| 2021-12-31 | -$398.37M 20-F · filed 2024-03-19 | -$375.59M 20-F · filed 2022-03-31 | |||
| 2021-06-30 | -$169.18M 6-K · filed 2021-08-23 | ||||
| 2020-12-31 | -$262.30M 20-F · filed 2023-03-30 | -$305.62M 20-F · filed 2021-04-02 | |||
| 2020-06-30 | -$179.32M 6-K · filed 2021-08-23 | ||||
| 2019-12-31 | -$102.86M 20-F/A · filed 2023-02-17 | -$132.79M 20-F · filed 2021-04-02 | |||
| 2018-12-31 | -$4.22M 20-F · filed 2021-04-02 |